SCHEMBL13624988

SCHEMBL13624988

NC(=O)CNc1ncc(C(N)=O)c(Nc2ccc3[nH]ncc3c2)n1

nearest known ligand 0.69

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SYK P43405 12/20 0.69
JAK3 P52333 1/20 0.55
IRAK4 Q9NWZ3 1/20 0.55
MAPK8 P45983 7/20 0.54
ZAP70 P43403 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13624765 0.92 SYK (0.69) SYKMAPK8ZAP70
SCHEMBL12137325 0.86 SYK (0.73) SYK
SCHEMBL13624695 0.85 SYK (0.69) SYKMAPK8ZAP70
SCHEMBL10241915 0.85 SYK (0.73) SYKJAK3IRAK4MAPK8
SCHEMBL10242654 0.85 SYK (0.73) SYKJAK3IRAK4MAPK8
SCHEMBL1353386 0.82 SYK (1.00) SYK
SCHEMBL1353383 0.82 SYK (1.00) SYK
SCHEMBL14977190 0.81 SYK (0.83) SYK
SCHEMBL14977189 0.81 SYK (0.83) SYK
SCHEMBL10242647 0.81 SYK (0.67) SYKJAK3IRAK4MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323993-B1 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS PORTOLA PHARM INC (US) 2015-06-03 EP disclosed
US-20140200198-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2014-07-17 US disclosed
WO-2009136995-A2 INHIBITORS OF SYK PROTEIN KINASE PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200198-A1 BORON-CONTAINING SMALL MOLECULES BTD, BCL6B, BBOX1 SYK 702/4885JAK3 1976/4885IRAK4 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.